Author: NSV

Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Ventyx Biosciences announces results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provides corporate update

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a

Read More
NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease

NorthSea Therapeutics receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the treatment of Intestinal Failure-Associated Liver Disease

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that one of its novel Structural Engineered Fatty Acids (SEFAs), SEFA-6179, has been granted Rare Pediatric Disease (RPD) Designation by the United States Food and

Read More
Achronix announces FPGA-Powered accelerated Automatic Speech Recognition solution

Achronix announces FPGA-Powered accelerated Automatic Speech Recognition solution

Achronix Semiconductor Corporation, a leader in high-performance FPGAs and embedded FPGA (eFPGA) IP, is proud to announce its latest innovation in partnership with Myrtle.ai — an accelerated automatic speech recognition (ASR) solution based on the Speedster7t FPGA. This transformative solution converts spoken language to text in over 1,000 concurrent real-time

Read More
Ventyx Biosciences announces positive results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis

Ventyx Biosciences announces positive results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely

Read More
Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier

Glydways, a leader in developing on-demand Personal Rapid Transit (PRT), has announced its $56 million Series B round, including the conversion of notes valued at more than $28 million and led by New Science Ventures with participation from The ACS Group and Gates Frontier. Khosla Ventures, Glydways first investor, is

Read More
Paragraf named Business of the Year in Cambridge glory parade

Paragraf named Business of the Year in Cambridge glory parade

Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted

Read More
Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform

Zeotap CDP, the easy, secure and impactful Customer Data Platform (CDP) has established a strategic partnership with Artefact, a global data consulting service specialist. This collaboration will help to deliver effective data-driven marketing while prioritising consumer privacy and security. Enterprises will benefit from a holistic and integrated approach that will

Read More
Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system

Read More
Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the

Read More
Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections

Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections

Read More
Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf acquires Cardea Bio to extend graphene electronics leadership

Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become

Read More
Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks

Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of

Read More